WCA Recommendations for the Long-Term Treatment of Social Phobia

ABSTRACT What is the best approach for treating patients with social phobia (social anxiety disorder) over the long term? Social phobia is the most common anxiety disorder, with reported prevalence rates of up to 18.7%. Social phobia is characterized by a marked and persistent fear of being observed or evaluated by others in social performance or interaction situations and is associated with physical, cognitive, and behavioral (ie, avoidance) symptoms. The onset of social phobia typically occurs in childhood or adolescence and the clinical course, if left untreated, is usually chronic, unremitting, and associated with significant functional impairment. Social phobia exhibits a high degree of comorbidity with other psychiatric disorders, including mood disorders, anxiety disorders, and substance abuse/dependence. Few people with social phobia seek professional help despite the existence of beneficial treatment approaches. The efficacy, tolerability, and safety of the selective serotonin reuptake inhibitors (SSRIs), evidenced in randomized clinical trials, support these agents as first-line treatment. The benzodiazepine clonazepam and certain monoamine oxidase inhibitors (representing both reversible and nonreversible inhibitors) may also be of benefit. Treatment of social phobia may need to be continued for several months to consolidate response and achieve full remission. The SSRIs have shown benefit in longterm treatment trials, while long-term treatment data from clinical studies of clonazepam are limited but support the drug's efficacy. There is also evidence for the effectiveness of exposure-based strategies of cognitive-behavioral therapy, and controlled studies suggest that the effects of treatment are generally maintained at long-term follow-up. In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months.

[1]  I. Holme,et al.  Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial , 2003, British Journal of Psychiatry.

[2]  M. Liebowitz,et al.  Results from a randomized, double-blind, multicenter trial of sertaline in the treatment of moderate-to-severe social phobia (social anxiety disorder) , 2002, European Neuropsychopharmacology.

[3]  P. Doraiswamy,et al.  Treatment of social anxiety disorder with citalopram , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  H. Wittchen,et al.  Epidemiology, patterns of comorbidity, and associated disabilities of social phobia. , 2001, The Psychiatric clinics of North America.

[5]  J. Davidson,et al.  Impact of generalized social anxiety disorder in managed care. , 2001, The American journal of psychiatry.

[6]  I. Holme,et al.  Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia , 2001, British Journal of Psychiatry.

[7]  I. McKinnon,et al.  Cigarette smoking and anxiety disorders. , 2001, JAMA.

[8]  R. Bowen,et al.  Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. , 2001, The American journal of psychiatry.

[9]  R. Bowen,et al.  Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. , 2000, Journal of clinical psychopharmacology.

[10]  M. Stein,et al.  Social phobia symptoms, subtypes, and severity: findings from a community survey. , 2000, Archives of general psychiatry.

[11]  P. Farvolden,et al.  Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI , 2000, Expert opinion on investigational drugs.

[12]  S Kasper,et al.  Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. , 2000, Journal of affective disorders.

[13]  R. Kessler The epidemiology, natural history, and pharmacoeconomics, of social anxiety and PTSD , 2000, European Neuropsychopharmacology.

[14]  H. Wittchen,et al.  Nicotine consumption in mental disorders: a clinical epidemiological perspective , 2000, European Neuropsychopharmacology.

[15]  H. Westenberg Neurobiology of anxiety disorders: Focus on neuroimaging , 2000, European Neuropsychopharmacology.

[16]  D. Baldwin Comprehensive treatment of social anxiety disorder , 2000, European Neuropsychopharmacology.

[17]  D. Stein Diagnostic dilemmas in social anxiety disorder and posttraumatic stress , 2000, European Neuropsychopharmacology.

[18]  J. Davidson,et al.  A placebo-controlled, double-blind study of pregabalin treatment of social phobia: Outcome and predictors of response , 2000, European Neuropsychopharmacology.

[19]  D. Stein,et al.  The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta‐analysis of randomized controlled trials , 2000, International clinical psychopharmacology.

[20]  P. Farvolden,et al.  The neurobiology of social phobia: From pharmacotherapy to brain imaging , 2000, Current psychiatry reports.

[21]  M. Antony,et al.  Phobic Disorders and Panic in Adults: A Guide to Assessment and Treatment , 2000 .

[22]  J. Rosenbaum,et al.  A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. , 2000, Journal of anxiety disorders.

[23]  F. Schneier Paroxetine in social phobia/social anxiety disorder , 2000 .

[24]  D. Cicchetti,et al.  Problems in developing an instrument for the rapid assessment of personality status , 2000, European Psychiatry.

[25]  M. Ansseau,et al.  [Guidelines for the treatment of anxiety disorders in adults]. , 2000, Revue medicale de Liege.

[26]  Dan J Stein,et al.  Functional brain imaging and pharmacotherapy in social phobia: Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[27]  J. Cottraux,et al.  Cognitive Behavior Therapy versus Supportive Therapy in Social Phobia: A Randomized Controlled Trial , 2000, Psychotherapy and Psychosomatics.

[28]  Dan J Stein,et al.  Functional brain imaging and pharmacotherapy in trichotillomania Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  T. T. Haug,et al.  The treatment of social phobia in general practice. is exposure therapy feasible? , 2000, Family practice.

[30]  M. Liebowitz,et al.  Low dopamine D(2) receptor binding potential in social phobia. , 2000, The American journal of psychiatry.

[31]  M. Stein,et al.  Trends in the prevalence of social phobia in the United States: a synthetic cohort analysis of changes over four decades , 2000, European Psychiatry.

[32]  A. Rossi,et al.  The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. , 1999, The Journal of clinical psychiatry.

[33]  M. Stein Coming face-to-face with social phobia. , 1999, American family physician.

[34]  Disability associated with social anxiety disorder , 1999, European Neuropsychopharmacology.

[35]  R. Kessler,et al.  Anxiety, mood, and substance abuse disorders: Patterns and correlates of comorbidity , 1999, European Neuropsychopharmacology.

[36]  J. A. Boer,et al.  Neurobiology of social anxiety disorder , 1999, European Neuropsychopharmacology.

[37]  C. Allgulander,et al.  Paroxetine in social anxiety disorder: a randomized placebo‐controlled study , 1999, Acta psychiatrica Scandinavica.

[38]  R. Kumar,et al.  Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder , 1999, European Neuropsychopharmacology.

[39]  M. Stein,et al.  The history, epidemiology, and differential diagnosis of social anxiety disorder. , 1999, The Journal of clinical psychiatry.

[40]  J. Davidson,et al.  Treatment of social phobia with gabapentin: a placebo-controlled study. , 1999, Journal of clinical psychopharmacology.

[41]  J. Ballenger Clinical guidelines for establishing remission in patients with depression and anxiety. , 1999, The Journal of clinical psychiatry.

[42]  R. Pioli,et al.  Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. , 1999, International clinical psychopharmacology.

[43]  R. Kessler,et al.  Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey , 1999, Psychological Medicine.

[44]  J. Davidson,et al.  Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. , 1999, The American journal of psychiatry.

[45]  R. Kessler,et al.  Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity , 1999, Psychological Medicine.

[46]  J. Oakman,et al.  Nefazodone in social phobia. , 1999, The Journal of clinical psychiatry.

[47]  D. Klein,et al.  Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. , 1998, Archives of general psychiatry.

[48]  J. Davidson,et al.  Discontinuation of clonazepam in the treatment of social phobia. , 1998, Journal of clinical psychopharmacology.

[49]  M. Stein,et al.  Subtypes of social phobia and comorbidity with depression and other anxiety disorders. , 1998, Journal of affective disorders.

[50]  J. Lépine,et al.  Social phobia and alcoholism: a complex relationship. , 1998, Journal of affective disorders.

[51]  M. Stein,et al.  Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. , 1998, JAMA.

[52]  R. Kessler,et al.  Social phobia subtypes in the National Comorbidity Survey. , 1998, The American journal of psychiatry.

[53]  D. Stein,et al.  Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. , 1998, Journal of affective disorders.

[54]  D. Klein,et al.  Imipramine in the treatment of social phobia. , 1998, Journal of clinical psychopharmacology.

[55]  M. Liebowitz,et al.  Placebo-controlled trial of moclobemide in social phobia , 1998, British Journal of Psychiatry.

[56]  H. Wittchen,et al.  Prevalence of mental disorders and psychosocial impairments in adolescents and young adults , 1998, Psychological Medicine.

[57]  Y. Lecrubier,et al.  Comorbidities in social phobia , 1997, International clinical psychopharmacology.

[58]  J. J. López-lbor,et al.  Social phobia: a debilitating disease that needs treatment , 1997 .

[59]  J. Davidson,et al.  Moclobemide in social phobia: a controlled dose-response trial. , 1997, Journal of clinical psychopharmacology.

[60]  H. Westenberg,et al.  Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. , 1997, The Journal of clinical psychiatry.

[61]  L. H. Taylor,et al.  Fluoxetine efficacy in social phobia. , 1997, The Journal of clinical psychiatry.

[62]  E. Kleinknecht,et al.  Cultural factors in social anxiety: a comparison of social phobia symptoms and Taijin kyofusho. , 1997, Journal of anxiety disorders.

[63]  C M Miner,et al.  The Brief Social Phobia Scale: a psychometric evaluation , 1997, Psychological Medicine.

[64]  J. Davidson,et al.  A 2‐Year Follow‐up of Social Phobia: Status After a Brief Medication Trial , 1996, The Journal of nervous and mental disease.

[65]  M. Ameringen,et al.  Paroxetine in social phobia. , 1996, The Journal of clinical psychiatry.

[66]  H. Wittchen,et al.  The impact of social phobia on quality of life , 1996, International clinical psychopharmacology.

[67]  M. Stein,et al.  Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. , 1996, Journal of clinical psychopharmacology.

[68]  M. Versiani,et al.  The long-term treatment of social phobia with moclobemide , 1996, International clinical psychopharmacology.

[69]  P. Bech,et al.  Quality of life in anxiety and social phobia , 1996, International clinical psychopharmacology.

[70]  M. Stein,et al.  Panic disorder or social phobia: which is worse? , 1996, Behaviour research and therapy.

[71]  R. Kessler,et al.  Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. , 1996, Archives of general psychiatry.

[72]  M. Humble,et al.  Social phobia: the clinical efficacy and tolerability of the monoamine oxidase ‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study , 1995, Acta psychiatrica Scandinavica.

[73]  K. Kobak,et al.  Sertraline for social phobia: a double-blind, placebo-controlled crossover study. , 1995, The American journal of psychiatry.

[74]  R. Heimberg,et al.  Dismantling cognitive-behavioral group therapy for social phobia. , 1995, Behaviour research and therapy.

[75]  E. Leinonen,et al.  Citalopram in the treatment of social phobia: a report of three cases. , 1994, Pharmacopsychiatry.

[76]  H. Westenberg,et al.  Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine , 1994, Psychopharmacology.

[77]  D. Beidel,et al.  Social phobia: a comparison of behavior therapy and atenolol. , 1994, Journal of consulting and clinical psychology.

[78]  M. Stein,et al.  Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. , 1994, The American journal of psychiatry.

[79]  J. Davidson,et al.  Treatment of social phobia with clonazepam and placebo. , 1993, Journal of clinical psychopharmacology.

[80]  E. Hollander,et al.  Buspirone in social phobia. , 1993, Journal of clinical psychopharmacology.

[81]  J. Rapoport,et al.  Obsessive compulsive disorder in children and adolescents: issues in management. , 1993, The Journal of clinical psychiatry.

[82]  T. Uhde,et al.  Elective mutism as a variant of social phobia. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[83]  M. Liebowitz,et al.  Pharmacotherapy of Social Phobia , 1992, British Journal of Psychiatry.

[84]  M. Weissman,et al.  Social Phobia: Comorbidity and Morbidity in an Epidemiologic Sample , 1992 .

[85]  J Gorman,et al.  Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. , 1992, Archives of general psychiatry.

[86]  H. Westenberg,et al.  Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor , 1992, European Neuropsychopharmacology.

[87]  M. Tancer,et al.  Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. , 1991, Archives of general psychiatry.

[88]  K. Krishnan,et al.  The Brief Social Phobia Scale. , 1991, The Journal of clinical psychiatry.

[89]  G. Styan,et al.  Relationship of social phobia with other psychiatric illness. , 1991, Journal of affective disorders.

[90]  L. Kirmayer,et al.  The Place of Culture in Psychiatric Nosology: Taijin Kyofusho and DSM-III-R , 1991, The Journal of nervous and mental disease.

[91]  D. Regier,et al.  Age at onset of selected mental disorders in five community populations. , 1990, Archives of general psychiatry.

[92]  D. Munjack,et al.  Clonazepam in the treatment of social phobia: a pilot study. , 1990, The Journal of clinical psychiatry.

[93]  M. Stein,et al.  Major depression in patients with social phobia. , 1990, The American journal of psychiatry.

[94]  M. Liebowitz,et al.  Tranylcypromine in social phobia. , 1988, Journal of clinical psychopharmacology.

[95]  R. Noyes,et al.  Anxiety symptoms distinguishing social phobia from panic and generalized anxiety disorders. , 1988, The Journal of nervous and mental disease.

[96]  E. Hollander,et al.  Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. , 1988, The Journal of clinical psychiatry.

[97]  R. Mattick,et al.  Treatment of severe social phobia: effects of guided exposure with and without cognitive restructuring. , 1988, Journal of consulting and clinical psychology.

[98]  J. Gorman,et al.  Phenelzine in social phobia. , 1986, Journal of clinical psychopharmacology.

[99]  M. Gelder,et al.  Exposure and anxiety management in the treatment of social phobia. , 1984, Journal of consulting and clinical psychology.

[100]  M. Gelder,et al.  Social Phobia: A Comparative Clinical Study , 1983, British Journal of Psychiatry.

[101]  R. Harpin,et al.  The Treatment of Social Phobia: Real‐life Rehearsal with Nonprofessional Therapists , 1981, The Journal of nervous and mental disease.

[102]  C. Macfie The year ... psychiatry. , 1980, The Medical journal of Australia.

[103]  M. Liebowitz,et al.  Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. , 2002, Journal of anxiety disorders.

[104]  R. Heimberg Current status of psychotherapeutic interventions for social phobia. , 2001, The Journal of clinical psychiatry.

[105]  D. Nutt,et al.  Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. , 2001, The Journal of clinical psychiatry.

[106]  J. Greist,et al.  Social anxiety disorder: an unrecognized problem in primary care. , 2001, The Journal of clinical psychiatry.

[107]  D. Stein,et al.  Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. , 2001, The Journal of clinical psychiatry.

[108]  M. Antony,et al.  Exposure-based strategies and social skills training. , 2000 .

[109]  P. Ninan Use of venlafaxine other psychiatric disorders , 2000, Depression and anxiety.

[110]  J. Bobes,et al.  Therapeutic advances: Paroxetine for the treatment of social anxiety disorder , 2000, Depression and anxiety.

[111]  D. Klein,et al.  Cognitive‐behavioral group therapy versus phenelzine in social phobia: Long term outcome , 1999, Depression and anxiety.

[112]  D. Nutt,et al.  Brain mechanisms of social anxiety disorder. , 1998, The Journal of clinical psychiatry.

[113]  J. Biederman,et al.  Attention-deficit/hyperactivity disorder: a life-span perspective. , 1998, The Journal of clinical psychiatry.

[114]  M. Stein,et al.  A direct-interview family study of generalized social phobia. , 1998, The American journal of psychiatry.

[115]  C. Essau,et al.  Häufigkeit und Komorbidität sozialer Ängste und sozialer Phobie bei Jugendlichen , 1998 .

[116]  H. Westenberg,et al.  Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. , 1998, The Journal of clinical psychiatry.

[117]  D. Pine,et al.  Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. , 1997, Journal of child and adolescent psychopharmacology.

[118]  The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. , 1997, European archives of psychiatry and clinical neuroscience.

[119]  J. Angst,et al.  Social phobia. , 1995, European archives of psychiatry and clinical neuroscience.

[120]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[121]  E. Hollander,et al.  Phenelzine and atenolol in social phobia. , 1990, Psychopharmacology bulletin.

[122]  P. Clayton,et al.  The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. , 1990, The Journal of clinical psychiatry.

[123]  J. Gorman,et al.  Psychopharmacological treatment of social phobia. , 1985, Psychopharmacology bulletin.

[124]  A. Mathews,et al.  Brief standard self-rating for phobic patients. , 1979, Behaviour research and therapy.

[125]  P. Shaw The Treatment of Social Phobia , 1979 .